Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 3;9(6):640. doi: 10.3390/biomedicines9060640

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

T-cell activation by EGFRvIII-BsAb. (a) CD69 expression on CD4+ and CD8+ T cells’ surface in response to target tumor cells or the EGFRvIII-BsAb. (b) The secreted levels of IFN-γ and IL-2 in culture supernatant detected after treatment with different EGFRvIII-BsAb concentrations by ELISA. (c) The cytotoxicity measurement of the EGFRvIII-BsAb and its parental antibodies or their combo treatment under low and middle antibody concentration by the LDH method (p < 0.0002 (***), p < 0.0001 (****)). (d) Dose-dependent antitumor activity evaluation of the EGFRvIII-BsAb on U87MG.ΔEGFR or U87MG (left). Dose-dependent antitumor activity evaluation of the EGFRvIII-BsAb compared with the EGFRvIII mAb and the CD3 mAb on U87MG.ΔEGFR cells (right). (e) Maximum cytotoxicity and EC₅₀ comparison among EGFRvIII-BsAb and EGFRvIII mAb or ADCC-attenuated EGFRvIII mAb counterpart. Cytotoxicity measurement by LDH release assay.